Volume 25, Issue 4 (December 2018)                   J Birjand Univ Med Sci. 2018, 25(4): 307-316 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nobakht Z, Vaghari Kharashtomi A, Sharifzadeh G. Comparison of the effect of alendronate and pamidronate on bone density of patients with osteoporosis. J Birjand Univ Med Sci.. 2018; 25 (4) :307-316
URL: http://journal.bums.ac.ir/article-1-2475-en.html
1- Islamic Azad University, Mashhad, Mashhad, Iran.
2- Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran. , Hadi_khorashadi@yahoo.com
3- Social Determinants of Health Research Center, Birjand University of Medical sciences, Birjand, Iran.
Abstract:   (870 Views)
Background and Aim: For the treatment of osteoporosis, bisphosphonates are commonly used as oral or injectable compounds. This study was conducted with the aim of comparing the effect of oral alendronate with injectable pamidronate on bone density changes in patients with osteoporosis.
Materials and Methods: The present study was a semi-experimental based on available evidence that was performed on patients with osteoporosis referred to Vali-e-asr Hospital in Birjand during the years 2013 to 2016. In addition, this intervention is a standard intervention that is routinely done. Patients in two groups treated for one year, in one group, they received oral alendronate and in the other group received injectable Pamidronate. Treatment with calcium and vitamin D was also performed in both groups. Dexamethasone densitometry (DEXA) was measured with a Dual-Energy X-ray absorptiometry (Hologic) device in the United States in both groups before and after treatment. Data were analyzed using Fisher's exact, t-paired and independent t-test at a significant level of (p≤0.05).
Results: Between all densitometric parameters of the spine, an only Z-score was improved after treatment with pamidronate or alendronate. The Densitometric parameters of the hip were improved in pamidronate group only. There was no statistical difference in the mean and frequency of changes in bone density indexes in the vertebrae and the hip after treatment compared to before, in both groups treated with alendronate or pamidronate.
Conclusion: The prescription of alendronate or pamidronate for one year can improve the Z-score of the sealed bone density, while the Z-score of hip bone density only improves in the treatment of pamidronate group. None of the two prescriptions had a particular advantage in changing the bone density index in the vertebrae, but pamidronate has better effect on the hip.
Full-Text [PDF 555 kb]   (147 Downloads)    
Type of Study: Original Article | Subject: Pharmacology
Received: 2018/04/11 | Accepted: 2018/07/21

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2019 All Rights Reserved | Journal of Birjand University of Medical Sciences

Designed & Developed by : Yektaweb